Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2026)

Alx Oncology Holdings has reported Non-Current Debt for 7 years, with the latest figure at $3.3 million in Q1 2026.

• Quarterly Non-Current Debt fell 59.97% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 59.97% YoY) and the FY2025 annual result came in at $4.5 million, down 52.14% from the prior year.
• Non-Current Debt fell to $3.3 million in Q1 2026 per ALXO's latest filing, from $4.5 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $9.8 million in Q3 2024 and troughed at $3.3 million in Q1 2026.
• A 5-year average of $8.2 million and a median of $9.5 million in 2023 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2024 and 2026: Non-Current Debt gained 2.72% in 2024, then tumbled 59.97% in 2026.
• Over 5 years, Non-Current Debt stood at $9.4 million in 2022, then climbed by 2.66% to $9.6 million in 2023, then decreased by 1.76% to $9.5 million in 2024, then tumbled by 52.14% to $4.5 million in 2025, then fell by 27.29% to $3.3 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $3.3 million, $4.5 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.